虫草素可消除甲氨蝶呤诱导的破骨细胞生成抑制

IF 0.4 4区医学 Q4 NUTRITION & DIETETICS

Current Topics in Nutraceutical Research Pub Date : 2023-08-30 DOI:10.37290/ctnr2641-452x.21:485-489

Lin Lei, Baohua Hao, Zhiyu Jia, Pengfei Qu

{"title":"虫草素可消除甲氨蝶呤诱导的破骨细胞生成抑制","authors":"Lin Lei, Baohua Hao, Zhiyu Jia, Pengfei Qu","doi":"10.37290/ctnr2641-452x.21:485-489","DOIUrl":null,"url":null,"abstract":"In this study, we have explored the reasons for the poor efficiency of 3′-deoxyadenosine in the treatment of rheumatoid arthritis. The effects of cordycepin and methotrexate on osteoclastogenesis were evaluated using the culture system of rat whole bone marrow cells and immunofluorescence staining with Kat1, a novel cell-surface antigen specifically expressed on rat osteoclasts. The effect of cordycepin on osteoclast formation was evaluated by tartaric acid-resistant phosphatase staining of bone marrow cell culture lines (pre-osteoclast formation lines) in which mesenchymal cells were removed. In the bone marrow culture system for evaluating osteoclastogenesis, methotrexate-induced suppression of osteoclastogenesis was abrogated only by the addition of cordycepin. In the pre-osteoclast formation system, cordycepin (3′-deoxyadenosine) was found to have no significant effect on osteoclast formation. To sum up, cordycepin should be carefully used in some cases of rheumatoid arthritis treated with methotrexate and in the severe stages of rheumatoid arthritis.","PeriodicalId":10976,"journal":{"name":"Current Topics in Nutraceutical Research","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2023-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cordycepin Abrogates Methotrexate-Induced Suppression of Osteoclastogenesis\",\"authors\":\"Lin Lei, Baohua Hao, Zhiyu Jia, Pengfei Qu\",\"doi\":\"10.37290/ctnr2641-452x.21:485-489\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In this study, we have explored the reasons for the poor efficiency of 3′-deoxyadenosine in the treatment of rheumatoid arthritis. The effects of cordycepin and methotrexate on osteoclastogenesis were evaluated using the culture system of rat whole bone marrow cells and immunofluorescence staining with Kat1, a novel cell-surface antigen specifically expressed on rat osteoclasts. The effect of cordycepin on osteoclast formation was evaluated by tartaric acid-resistant phosphatase staining of bone marrow cell culture lines (pre-osteoclast formation lines) in which mesenchymal cells were removed. In the bone marrow culture system for evaluating osteoclastogenesis, methotrexate-induced suppression of osteoclastogenesis was abrogated only by the addition of cordycepin. In the pre-osteoclast formation system, cordycepin (3′-deoxyadenosine) was found to have no significant effect on osteoclast formation. To sum up, cordycepin should be carefully used in some cases of rheumatoid arthritis treated with methotrexate and in the severe stages of rheumatoid arthritis.\",\"PeriodicalId\":10976,\"journal\":{\"name\":\"Current Topics in Nutraceutical Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2023-08-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Topics in Nutraceutical Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.37290/ctnr2641-452x.21:485-489\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"NUTRITION & DIETETICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Topics in Nutraceutical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37290/ctnr2641-452x.21:485-489","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}

引用次数: 0

摘要

在本研究中，我们探讨了3 ' -脱氧腺苷治疗类风湿关节炎疗效不佳的原因。采用大鼠全骨髓细胞培养系统和大鼠破骨细胞表面抗原Kat1免疫荧光染色，观察虫草素和甲氨蝶呤对破骨细胞形成的影响。通过去除间充质细胞的骨髓细胞培养系(破骨细胞形成前系)的抗酒石酸磷酸酶染色来评估虫草素对破骨细胞形成的影响。在评估破骨细胞生成的骨髓培养系统中，甲氨蝶呤诱导的破骨细胞生成抑制仅通过添加虫草素来消除。在破骨细胞形成前系统中，虫草素(3′-脱氧腺苷)对破骨细胞形成无显著影响。综上所述，在一些用甲氨蝶呤治疗的类风湿关节炎病例和类风湿关节炎的严重阶段，应谨慎使用虫草素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Cordycepin Abrogates Methotrexate-Induced Suppression of Osteoclastogenesis

In this study, we have explored the reasons for the poor efficiency of 3′-deoxyadenosine in the treatment of rheumatoid arthritis. The effects of cordycepin and methotrexate on osteoclastogenesis were evaluated using the culture system of rat whole bone marrow cells and immunofluorescence staining with Kat1, a novel cell-surface antigen specifically expressed on rat osteoclasts. The effect of cordycepin on osteoclast formation was evaluated by tartaric acid-resistant phosphatase staining of bone marrow cell culture lines (pre-osteoclast formation lines) in which mesenchymal cells were removed. In the bone marrow culture system for evaluating osteoclastogenesis, methotrexate-induced suppression of osteoclastogenesis was abrogated only by the addition of cordycepin. In the pre-osteoclast formation system, cordycepin (3′-deoxyadenosine) was found to have no significant effect on osteoclast formation. To sum up, cordycepin should be carefully used in some cases of rheumatoid arthritis treated with methotrexate and in the severe stages of rheumatoid arthritis.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Current Topics in Nutraceutical Research 医学-药学

CiteScore

1.10

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Current Topics in Nutraceutical Research is an international, interdisciplinary broad-based peer reviewed scientific journal for critical evaluation of research on chemistry, biology and therapeutic applications of nutraceuticals and functional foods. The major goal of this journal is to provide peer reviewed unbiased scientific data to the decision makers in the nutraceutical and food industry to help make informed choices about development of new products. To this end, the journal will publish two types of review articles. First, a review of preclinical research data coming largely from animal, cell culture and other experimental models. Such data will provide basis for future product development and/or human research initiatives. Second, a critical evaluation of current human experimental data to help market and deliver the product for medically proven use. This journal will also serve as a forum for nutritionists, internists, neurologists, psychiatrists, and all those interested in preventive medicine. The common denominator of all of the topic to be covered by the journal must include nutraceuticals and/functional food. The following is an example of some specific areas that may be of interest to the journal. i) Role of vitamins, minerals, antioxidants and phytonutrients on cardiovascular health, cancer, diabetes, ocular health, mental health, men’s health, women’s health, infant nutrition, ii) Role of herbals on human health, iii) Dietary supplements and sleep, iv) Components of diet that may have beneficial effect on human health, v) regulation of apoptosis and cell viability, vi) Isolation and characterization of bioactive components from functional foods, vii) Nutritional genomics, and viii) Nutritional proteomics.